Conclusion of an agreement with Berger&Kraft Medical Sp. z o.o. for research, development and manufacturing services using Syglass technology

The Management Board of Sygnis S.A. with its registered office in Gdansk (hereinafter: the Company) informs that today it has concluded an agreement with Berger&Kraft Medical Sp. z o.o. with its registered office in Warsaw, the subject of which is the development of new optical technologies and the creation on their basis of revolutionary products used in skin therapy. The aim of the project is to develop the technologies, which will then be covered by patent protection. As part of the project, the Company will be responsible for providing optical solutions, working on the basis of the use of lasers in the devices, using Syglass technology, co-created by the Company (the world’s first 3D printing technology from low-temperature glass). The project will be implemented between March and the end of September 2023.

The Company’s Management Board points out that the Matex Lab Group (of which Berger&Kraft Medical Sp. z o.o. is a part) is a leader in the international aesthetic medicine and wellness market, where the market for beauty industry devices used in skin therapy alone is worth more than $20 billion (annually), with an average annual growth rate (CAGR) of 5.5%.

This agreement, is the first on a framework cooperation for the application implementation of Syglass technology for the non-scientific industry, at the same time in line with the pivot in action the Company has developed in 2022 (moving away from the sale of machines, to the sale of products resulting from Syglass machines/applications).